Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer - Evidence of effect modification by prostate size

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 345-352

  Fowke, Jay H ^a   Motley, Saundra ^a   Dai, Qi ^a   Concepcion, Raoul ^b   Barocas, Daniel A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Urology Associates   (United States)

Author keywords

Bias; High grade prostatic intraepithelial neoplasia; Human; Obesity; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; LEPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; WAIST HIP RATIO;

AGED; BIOLOGICAL MARKERS; BIOPSY; BODY WEIGHTS AND MEASURES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; OBESITY; ORGAN SIZE; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK;

EID: 84870344072     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.010     Document Type: Article

References (52)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
2. Bassett W.W., Cooperberg M.R., Sadetsky N., Silva S., DuChane J., Pasta D.J., Chan J.M., Anast J.W., Carroll P.R., Kane C.J. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 2005, 66:1060-1065.
3. Motamedinia P., Korets R., Spencer B.A., Benson M.C., McKiernan J.M. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology 2008, 72:1106-1110.
4. Amling C.L., Riffenburgh R.H., Sun L., Moul J.W., Lance R.S., Kusuda L., Sexton W.J., Soderdahl D.W., Donahue T.F., Foley J.P., Chung A.K., McLeod D.G. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 2004, 22:439-445.
5. Siddiqui S.A., Inman B.A., Sengupta S., Slezak J.M., Bergstralh E.J., Leibovich B.C., Zincke H., Blute M.L. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer 2006, 107:521-529.
6. Freedland S.J., Terris M.K., Presti J.C., Amling C.L., Kane C.J., Trock B., Aronson W.J. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J. Urol. 2004, 172:520-524.
7. Bassett J.K., Severi G., Baglietto L., MacInnis R.J., Hoang H.N., Hopper J.L., English D.R., Giles G.G. Weight change and prostate cancer incidence and mortality. Int. J. Cancer 2012, n/a.
8. MacInnis R., English D. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006, 17:989-1003.
9. Wallstrom P., Bjartell A., Gullberg B., Olsson H., Wirfalt E. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br. J. Cancer 2009, 100:1799-1805.
10. Rodriguez C., Patel A.V., Mondul A.M., Jacobs E.J., Thun M.J., Calle E.E. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am. J. Epidemiol. 2005, 161:147-152.
11. Giovannucci E., Rimm E., Stampfer M., Colditz G.A., Willett W.C. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998, 9:3-9.
12. Kasper J.S., Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2056-2062.
13. Leitzmann M.F., Ahn J., Albanes D., Hsing A.W., Schatzkin A., Chang S.C., Huang W.Y., Weiss J.M., Danforth K.N., Grubb R.L., Andriole G.L. Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control 2008, 19:1267-1276.
14. Festa A., D'Agostino R., Williams K., Karter A.J., Mayer-Davis E.J., Tracy R.P., Haffner S.M. The relation of body fat mass and distribution to markers of chronic inflammation. Int. J. Obes. Relat. Metab. Disord. 2001, 25:1407-1415.
15. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999, 22:1971-1977.
16. Baillargeon J., Rose D.P. Obesity, adipokines, and prostate cancer (review). Int. J. Oncol. 2006, 28:737-745.
17. Price R.S., Cavazos D.A., De Angel R.E., Hursting S.D., deGraffenried L.A. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012, 15:135-143.
18. Fowke J.H., Matthews C.E. PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate 2010, 70:120-125.
19. Fowke J.H., Signorello L.B., Chang S.S., Matthews C.E., Buchowski M.S., Cookson M.S., Ukoli F.A., Blot W.J. Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian men. Cancer 2006, 107:2361-2367.
20. Fowke J.H., Signorello L.B., Underwood W., Ukoli F.A., Blot W.J. Obesity and prostate cancer screening among African-American and Caucasian men. Prostate 2006, 66:1371-1380.
21. Fagan H.B., Wender R., Myers R.E., Petrelli N. Obesity and cancer screening according to race and gender. J. Obes. 2011, 2011:218250.
22. Johnson J., Bowker S., Richardson K., Marra C. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011, 54:2263-2271.
23. Fowke J.H., Motley S.S., Wills M., Cookson M.S., Concepcion R.S., Eckstein C.W., Chang S.S., Smith J.A. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control 2007, 18:375-384.
24. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Lieber M.M., Cespedes R.D., Atkins J.N., Lippman S.M., Carlin S.M., Ryan A., Szczepanek C.M., Crowley J.J., Coltman C.A. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349:213-222.
25. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 2000, 21:697-738.
26. Fisher F.M., McTernan P.G., Valsamakis G., Chetty R., Harte A.L., Anwar A.J., Starcynski J., Crocker J., Barnett A.H., McTernan C.L., Kumar S. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm. Metab. Res. 2002, 34:650-654.
27. Motoshima H., Wu X., Sinha M.K., Hardy V.E., Rosato E.L., Barbot D.J., Rosato F.E., Goldstein B.J. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 2002, 87:5662-5667.
28. Cote M., Mauriege P., Bergeron J., Almeras N., Tremblay A., Lemieux I., Despres J.P. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J. Clin. Endocrinol. Metab. 2005, 90:1434-1439.
29. Rajala M.W., Scherer P.E. Minireview: the adipocyte - at the crossroads of energy homeostatis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
30. Montironi R., Mazzucchelli R., Lopez-Beltran A., Scarpelli M., Cheng L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU Int. 2011, 108:1394-1401.
31. Epstein J.I., Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J. Urol. 2006, 175:820-834.
32. Augustin H. Obesity and prostate cancer - an ambiguous relationship. Eur. J. Cancer 2007, 43:1114-1116.
33. Meyerhardt J.A., Ma J., Courneya K.S. Energetics in colorectal and prostate cancer. J. Clin. Oncol. 2010, 28:4066-4073.
34. Stewart S.B., Freedland S.J. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol. Oncol.: Seminars Original Invest. 2011, 29:476-486.
35. Redman M.W., Tangen C.M., Goodman P.J., Lucia M.S., Coltman C.A., Thompson I.M. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. 2008, 1:174-181.
36. Mellon J.K. The finasteride prostate cancer prevention trial (PCPT) Gçô What have we learned?. Eur. J. Cancer 2005, 41:2016-2022.
37. Kristal A.R., Arnold K.B., Schenk J.M., Neuhouser M.L., Weiss N., Goodman P., Antvelink C.M., Penson D.F., Thompson I.M. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J. Urol. 2007, 177:1395-1400.
38. Giovannucci E., Rimm E.B., Chute C., Kawachi I., Colditz G.A., Stampfer M., Willet W.C. Obesity and benign prostatic hyperplasia. Am. J. Epidemiol. 1994, 140:989-1002.
39. Burke J.P., Rhodes T., Jacobson D.J., McGree M.E., Roberts R.O., Girman C.J., Lieber M.M., Jacobsen S.J. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am. J. Epidemiol. 2006, 164:41-46.
40. Parsons J.K., Carter H.B., Partin A.W., Windham B.G., Metter E.J., Ferrucci L., Landis P., Platz E.A. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 2006, 91:2562-2568.
41. Meigs J.B., Mohr B., Barry M.J., Collins M.M., McKinlay J.B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J. Clin. Epidemiol. 2001, 54:935-944.
42. Fowke J.H., Motley S.S., Cookson M.S., Concepcion R., Chang S.S., Wills M.L., Smith J.A. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2006, 10:137-142.
43. J.H. Fowke, S. Phillips, T. Koyama, S. Byerly, R. Concepcion, S.S. Motley, P.E. Clark, Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume, BJU Int., 2012 [epub ahead of print].
44. Okorodudu D.O., Jumean M.F., Montori V.M., Romero-Corral A., Somers V.K., Erwin P.J., Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int. J. Obes. (Lond) 2010, 34:791-799.
45. Romero-Corral A., Somers V.K., Sierra-Johnson J., Thomas R.J., Collazo-Clavell M.L., Korinek J., Allison T.G., Batsis J.A., Sert-Kuniyoshi F.H., Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. Int. J. Obes. (Lond) 2008, 32:959-966.
46. Shah N.R., Braverman E.R. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS ONE 2012, 7:e33308.
47. Wannamethee S.G., Shaper A.G., Morris R.W., Whincup P.H. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am. J. Clin. Nutr. 2005, 81:1313-1321.
48. Colli S., Silveira Cavalcante F., Peixoto Martins M., Sampaio F.J., da Fonte Ramos C. Leptin role in the rat prostate ventral lobe. Fertil. Steril. 2011, 95:1490-1493.
49. Chang S., Hursting S.D., Contois J.H., Strom S.S., Yamamura Y., Babaian R.J., Troncoso P., Wheeler P.T.S.M., Amos C.I., Spitz M.R. Leptin and prostate cancer. Prostate 2001, 46:62-67.
50. Stattin P., Kaaks R., Johansson R., Gislefoss R., Soderberg S., Alfthan H., Stenman U.H., Jellum E., Olsson T. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2003, 12:474-475.
51. Ribeiro R., Lopes C., Mederos R. Leptin and prostate: implications for cancer prevention - overview of genetics and molecular interactions. Eur. J. Cancer Prev. 2004, 13:359-368.
52. Ezzati M., Martin H., Skjold S., Vander H.S., Murray C.J. Trends in national and state-level obesity in the USA after correction for self-report bias: analysis of health surveys. J. R. Soc. Med. 2006, 99:250-257.